Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Anti-malarial Drugs Market Insights
Malaria has affected the tropical regions in the world including Africa and Asia, Central and South America, Haiti and the Dominican Republic, some parts of Middle East, and some Pacific islands. The increasing cases of traveler’s malaria is one of the factors contributing to growth of the market. Every year, thousands of people worldwide travel to such malaria affected regions, which is expected to increase the risk of infection. For instance, according to Global Health, Division of Parasitic Diseases and Malaria, and (CDC), each year, around 2,000 cases of malaria are diagnosed in the U.S. To avoid the increasing number of patient pool and to reduce the risk of traveler’s malaria, travelers are being advised by the regulatory authorities to have the antimalarial medicines with them.
The global anti-malarial drugs market was valued at US$ 839.1 million in 2019 and is expected to exhibit a CAGR of 4.4% during the forecast period (2019–2027).
Figure 1. Global Anti-malarial Drugs Market Value (US$ Mn) & Y-o-Y Growth Analysis, (2016-2027)
Source: Coherent Market Insights Analysis (2019)
Increasing research and development activities, in order to develop novel treatment approach and collaboration among the key players are expected to drive the market growth
Medicines for Malaria Venture (MMV) is a not-for-profit public-private partnership, which was established in 1999, with an aim to reduce the burden of malaria in disease-endemic countries by developing novel treatment options. Many of the key pharmaceutical companies have been collaborating with MMV in order to develop novel drug entity for the treatment of malaria. For instance, in December 2019, Ipca Laboratories entered into a collaboration agreement with Medicines for Malaria Venture to develop a novel antimalarial co-formulation, Atoguanil, a combination of atovaquone and proguanil.
Moreover, rising funding by regional governments is significantly contributing to growth of the global anti-malaria drugs market. These funding are expected to give opportunity for research institutes such as Medicines for Malaria Venture, in order to continue the research studies for potential lead candidates targeting malaria. For instance, in November 2017, United States Agency for International Development (USAID) granted funding of US$ 9 million to Medicines for Malaria Venture for 5 years to conduct the three project including pharmacovigilance study of Pyramax (pyronaridine-artesunate), SERC Phase III study to develop a single-exposure radical cure, and to study the efficacy of DSM265, a potential single-exposure radical cure.
Adverse effects and risks associated with anti-malaria drugs is expected to hamper the global anti-malarial drugs market growth
Most of the anti-malaria drugs are associated with severe side effects, which is expected to decrease demand for these drugs. For instance, Mefloquine may lead to nausea, vomiting, abdominal pain, headache, insomnia, and vivid dreams. Some other side effects such as dizziness, loss of balance, acute anxiety, depression, restlessness, confusion, and others are also associated with Mefloquine. Such factors are expected to hamper the market growth.
Global Anti-malarial Drugs Market- Regional Analysis
On the basis of region, the global anti-malarial drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, Africa is expected to hold a dominant position in the market, owing to increasing risk of malaria in the region. For instance, according to the WHO, around 92% of malaria cases in the world occurs in the Sub- Saharan African region. WHO also estimated that, in 2017, among the five countries, which were accounted for nearly half of all malaria cases worldwide, 4 countries were from Africa region including Nigeria (25%), Democratic Republic of Congo (11%), Mozambique (5%), and Uganda (4%).
Moreover, Asia Pacific anti-malarial drugs market is expected to exhibit significant growth over the forecast period, owing to increasing regulatory approval of the products, and presence of major pharmaceutical companies such as Ipca Laboratories, Zydus Cadila, Ranbaxy, and others in the emerging economies in Asia Pacific region including India, China, and others.
Figure 2: Global Anti-malarial Drugs Market Share (%), By Region
Source: Coherent Market Insights Analysis (2019)
Global Anti-malarial Drugs Market - Competitive Landscape
Key players operating in the global anti-malarial drugs market include Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, and Roche Inc.